ResearcherHomi Bhabha National InstituteActive in the last 2 years
Anant Ramaswamy
Matched on ORCID iD 0000-0002-8169-4264; OpenAlex author ID A5050313092. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 3, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2017: 1 paper · 2018: 2 papers · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper
Papers 7
- Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2024.06.004↗
- Practice Patterns and Survival in Patients with Resected Pancreatic Ductal Adenocarcinomas (PDAC) - Results from the Multicentre Indian Pancreatic & Periampull… First author DOI 10.1007/s12029-023-00936-1↗
- Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysis. Co-author DOI 10.4103/ijmr.ijmr_980_21↗
- Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving evidence. Co-author DOI 10.1016/j.surg.2021.10.018↗
- Treatment practices for metastatic pancreatic cancer: Can we deliver an appropriately efficacious and safe regimen in Indian patients? First author DOI 10.4103/ijc.ijc_552_17↗
- Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre. Last author DOI 10.4103/ijmr.ijmr_249_17↗
- Nontrial, real-world outcomes in unresectable locally advanced pancreatic cancer: Chemotherapy and chemoradiation is the standard while surgery is uncommon. First author DOI 10.4103/ijc.ijc_377_17↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Vikas S. Ostwal · 7 shared papers, 2017–2024 · strength 0.90
- Paper Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.hpb.2024.06.004↗
- Paper Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of … DOI 10.4103/ijmr.ijmr_980_21↗
- Paper Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving … DOI 10.1016/j.surg.2021.10.018↗
- Shailesh Vinayak Shrikhande · 6 shared papers, 2017–2024 · strength 0.72
- Paper Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.hpb.2024.06.004↗
- Paper Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving … DOI 10.1016/j.surg.2021.10.018↗
- Paper Practice Patterns and Survival in Patients with Resected Pancreatic Ductal Adenocarcinomas (PDAC) - Results from the Mu… DOI 10.1007/s12029-023-00936-1↗
- Vikram Anil Chaudhari · 3 shared papers, 2022–2024 · strength 0.47
- Paper Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.hpb.2024.06.004↗
- Paper Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving … DOI 10.1016/j.surg.2021.10.018↗
- Paper Practice Patterns and Survival in Patients with Resected Pancreatic Ductal Adenocarcinomas (PDAC) - Results from the Mu… DOI 10.1007/s12029-023-00936-1↗
- Manish Suresh BHANDARE · 3 shared papers, 2022–2024 · strength 0.47
- Paper Differential impact of incrementally elevated CA 19-9 levels on prognosis of resected pancreatic ductal adenocarcinoma. DOI 10.1016/j.hpb.2024.06.004↗
- Paper Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving … DOI 10.1016/j.surg.2021.10.018↗
- Paper Practice Patterns and Survival in Patients with Resected Pancreatic Ductal Adenocarcinomas (PDAC) - Results from the Mu… DOI 10.1007/s12029-023-00936-1↗
- Bhawna Sirohi · 1 shared paper, 2022 · strength 0.14
- Abhishek Mitra · 1 shared paper, 2022 · strength 0.14
- Shivendra Singh · 1 shared paper, 2023 · strength 0.12
- Vaibhav Kumar Varshney · 1 shared paper, 2023 · strength 0.12
- Adarsh Chaudhary · 1 shared paper, 2023 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.